ImmunityBio (IBRX) has provided an announcement.
ImmunityBio, Inc. recently announced that the FDA approved its Anktiva® drug for a specific type of bladder cancer, signaling a potential breakthrough in treatment options. Additionally, the company is contemplating a significant expansion of its 2015 Equity Incentive Plan, proposing to increase the authorized shares for issuance by nearly 20 million, a decision pending stockholder vote at the upcoming annual meeting. This news could influence the company’s stock performance, as it reflects both a critical regulatory milestone and a strategic corporate development.
See more insights into IBRX stock on TipRanks’ Stock Analysis page.
